-
β-Elemene: Mechanisms and Cell-Model Evidence
2026-08-20
β-Elemene, also called Levo-β-elemene, is a C15H24 sesquiterpene used in apoptosis, metabolic, inflammation, and neuroprotection research. In a 3T3-L1 adipocyte model, β-elemene reduced lipid accumulation and improved insulin-resistance-associated changes through AMPK pathway activation.
-
Measuring Drug Responses in Cancer In Vitro
2026-08-20
Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for separating growth inhibition from cell killing and interpreting their distinct proportions and timing, improving the design of in vitro studies and the evaluation of cancer epigenetics experiments.
-
LY2603618: Chk1 Inhibitor Workflow Guide
2026-08-19
LY2603618 enables controlled interrogation of Chk1-dependent replication-stress survival, G2/M checkpoint signaling, and chemotherapy sensitization. This workflow connects DNA-damage readouts with the thioredoxin–ribonucleotide reductase axis to improve responder profiling in non-small cell lung cancer research.
-
Azilsartan: Reframing AT1 Signaling in Neuroinflammation
2026-08-19
Azilsartan (TAK-536) offers translational researchers a precise way to interrogate AT1 receptor signaling across cardiovascular and neuroinflammation models. Drawing on a 2024 study of gastrodin, microglia-conditioned media, reactive astrocytes, and the RAS–SIRT3 axis, this article outlines how to use AT1 blockade to separate pathway causality from broad anti-inflammatory effects.
-
Metabolic Intervention Amplifies Ferroptosis and Cuproptosis
2026-08-18
Zhang et al. developed a copper–tannic acid/liposome nanosystem that packages STF-31 to inhibit glycolysis and compensatory NAD+ metabolism. By reducing glucose, NAD+, NADPH, ATP, glutathione synthesis, and copper efflux, the platform co-sensitized tumors to ferroptosis and cuproptosis while also promoting immunogenic cell death and antitumor T-cell activity.
-
Flubendazole: Autophagy Research Guide
2026-08-18
Flubendazole is a benzimidazole derivative supplied as a research-use autophagy activator. Its defined chemical identity, DMSO handling profile, and evidence boundaries support controlled autophagy modulation research without implying direct antifibrotic or clinical activity.
-
TaqI Restriction Endonuclease: Practical Protocol
2026-08-17
TaqI Restriction Endonuclease provides rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA when the TCGA recognition site is present. It is intended for scientific research workflows such as cloning and DNA analysis, not for diagnostic, clinical, or medical use.
-
SGI-1027 and Everolimus in Renal Cancer
2026-08-17
A 2024 Advanced Science study identifies SGI-1027 as an inducer of methuosis in renal cancer and shows that it cooperates with everolimus to trigger lysosomal membrane permeability, apoptosis, and GSDME-dependent pyroptosis. The findings expand the pharmacology of this DNA methyltransferase inhibitor and suggest a preclinical strategy for addressing everolimus resistance through combined epigenetic and lysosome-associated mechanisms.
-
Chloramphenicol: Selection With Transmission in Mind
2026-08-16
Chloramphenicol is more than a plasmid-selection antibiotic: it is a controllable variable in experiments studying plasmid maintenance, localization, and transfer. This guide connects its ribosomal mechanism and formulation requirements with the transmission-focused findings of a recent CREC study.
-
HCMV UL88 Targets MyD88 to Limit Innate Immunity
2026-08-15
Kumar and colleagues identify the HCMV tegument protein UL88 as a viral antagonist that associates with and reduces the innate immune adaptor MyD88. Their experiments connect UL88-dependent MyD88 regulation with NF-κB signaling, soluble antiviral activity, interferon-stimulated gene expression, and virus spread between myeloid cells and fibroblasts.
-
Pentoxifylline and Preterm Monocyte Hyperinflammation
2026-08-14
Schüller et al. showed that pentoxifylline suppresses LPS-induced inflammatory activation in monocytes from preterm infants, with effects spanning surface phenotype, cytokine release, phagocytosis, and TLR4 signaling. The age-stratified whole-blood model provides a useful framework for evaluating neonatal immunomodulation without assuming that adult sepsis biology applies directly to preterm infants.
-
E-64: From Protease Control to Viral Inflammation
2026-08-14
E-64 is an irreversible L-trans-epoxysuccinyl peptide that gives translational researchers a practical way to interrogate cysteine protease activity, cathepsin biology, invasion, and cell-death phenotypes. By placing this benchmark inhibitor alongside evidence that viral proteins regulate RIPK3 degradation and necroptosis, this article develops a cautious strategy for connecting protease activity with inflammatory disease mechanisms without overstating direct causality.
-
Linoleic Acid (C18:2): Protocol Guide
2026-08-13
This guide explains how to use Linoleic Acid (C18:2(9Z,12Z), SKU C3108) in oxidative stress, erythrocyte, membrane, migration, and nutritional deficiency workflows. It is suited to freshly prepared solvent-based experiments, but not to aqueous-only protocols or studies that require long-term stock-solution stability.
-
Reactive Oxygen Species Assay Kit for Mitophagy
2026-08-13
Learn how to use a DHE-based Reactive Oxygen Species Assay Kit to quantify intracellular superoxide in live-cell fibrosis and mitophagy experiments. The workflow emphasizes treatment-response design, PINK1–Parkin interpretation, controls, and troubleshooting rather than treating fluorescence as a standalone disease marker.
-
TaqI Restriction Endonuclease Protocol
2026-08-12
TaqI Restriction Endonuclease provides rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA at the 5′-TCGA-3′ recognition site. It is intended for controlled research workflows such as cloning and DNA mapping, not for diagnostic or medical use.